• Iaso 2024 Conference Schedule

    Iaso will be attending several industry conferences in 2024. Look for us at these upcoming conferences. World Vaccine Congress Washington 2024 April 1-4, 2024 Walter E. Washington Convention Center, [...]

    Published On: February 29, 2024
  • Iaso Selected for the Renaissance Venture Capital Startup Hotlist

    Iaso Therapeutics has been included on the @Renaissance Venture Capital Spring 2023 Startup Hotlist! The Hotlist features some of the most promising early-stage companies from the Midwest, curated from hundreds of recommendations from VC [...]

    Published On: June 10, 2023
  • Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing

    Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.

    Published On: January 25, 2023
  • Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research

    The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the development of novel technologies [...]

    Published On: March 14, 2022
  • Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseases

    Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, MI, 07/15/2021 – Iaso Therapeutics, INC. has been awarded a National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovation Research [...]

    Published On: February 11, 2022
  • Building Better Vaccines: Iaso Therapeutics

    Vaccines have dominated the news. With the COVID-19 pandemic, stories about vaccines have been a daily occurrence. They range from concerns about safety to vaccination rates and distribution. They highlight the amazing science that [...]

    Published On: June 1, 2021
  • Iaso Therapeutics secures investment from Michigan State University’s Student Venture Capital Fund

    East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in an annual class project [...]

    Published On: April 26, 2021
  • Iaso Therapeutics Invited to TRECS Workshop

    East Lansing, MI – Iaso Therapeutics (Iaso) has received a selective invitation to participate in the National Cancer Institute (NCI) Translational Resources to Expedite Commercialization Success Workshop (TRECS WORKSHOP). Iaso will participate in the [...]

    Published On: February 25, 2021
  • ‘An immense opportunity’: How LEAP wants Greater Lansing to become a med-tech hub

    Craig Lyons Lansing State Journal LANSING – When Herbert Kavunja joined Iaso Therapeutics as its chief scientist and sole employee, he faced a steep learning curve. He had to figure out how to write [...]

    Published On: February 8, 2021
  • Iaso Therapeutics Receives Phase I SBIR Grant from the National Cancer Institute

    Iaso Therapeutics received a Phase I SBIR grant from the National Cancer Institute (NCI). The grant is to study the feasibility of developing a cancer vaccine against breast cancer including triple negative breast cancer [...]

    Published On: October 15, 2020
  • Iaso Therapeutics Receives Phase I SBIR Grant from the National Science Foundation

    Iaso Therapeutics received a Phase I SBIR grant from the National Science Foundation (NSF). The grant is to study the feasibility of commercializing Iaso’s mutant Qβ (mQβ) virus-like particle. The mQβ particles are a [...]

    Published On: June 20, 2019